CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 19 2024 - 4:05PM
Business Wire
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a
leading precision medicine company focused on the discovery,
development, and commercialization of clinically differentiated,
high-value healthcare solutions for transplant patients and
caregivers — today announced that, on April 15, 2024, CareDx
granted an option to purchase 700,706 shares of CareDx’s common
stock (the “Inducement Option”) and 487,804 restricted stock units
(the “Inducement RSUs” ) to John Hanna, CareDx’s newly appointed
President and Chief Executive Officer. The Inducement Option and
the Inducement RSUs were approved by the Compensation and Human
Capital Committee of CareDx’s board of directors on March 25, 2024,
and were an inducement material to Mr. Hanna’s employment with
CareDx in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Option has an exercise price of $8.20 and will
vest over four years, with 25% of the total number of shares
subject to the Inducement Option vesting on April 15, 2025, the
one-year anniversary of the date of commencement of Hanna’s
employment with CareDx, and 1/48th of the total number of shares
subject to the Inducement Option vesting at the end of each
calendar month thereafter, subject in each case to Hanna’s
continued services with CareDx on each vesting date. The Inducement
RSUs will vest in four equal, annual installments beginning on
April 15, 2025, the one-year anniversary of the date of
commencement of Hanna’s employment with CareDx, subject in each
case to Hanna’s continued services with CareDx on each vesting
date.
CareDx is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the equity grants.
These forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including general economic and market
factors; and other risks discussed in CareDx’s filings with the
SEC, including the Annual Report on Form 10-K for the fiscal year
ended December 31, 2023 filed by CareDx with the SEC on February
28, 2024, and other reports that CareDx has filed with the SEC. Any
of these may cause CareDx’s actual results, performance, or
achievements to differ materially and adversely from those
anticipated or implied by CareDx’s forward-looking statements.
CareDx expressly disclaims any obligation, except as required by
law, or undertaking to update or revise any such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240419730072/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Sep 2024 to Oct 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Oct 2023 to Oct 2024